S&P 500   3,783.28 (-0.20%)
DOW   30,273.87 (-0.14%)
QQQ   281.98 (-0.05%)
AAPL   146.40 (+0.21%)
MSFT   249.20 (+0.13%)
META   138.98 (-0.93%)
GOOGL   101.43 (-0.21%)
AMZN   120.95 (-0.12%)
TSLA   240.81 (-3.46%)
NVDA   132.09 (+0.32%)
NIO   16.04 (-4.12%)
BABA   84.39 (+0.33%)
AMD   67.94 (+0.06%)
T   15.93 (-0.99%)
MU   54.73 (+1.43%)
CGC   3.07 (-2.23%)
F   12.51 (+1.21%)
GE   67.44 (-0.15%)
DIS   100.80 (-0.63%)
AMC   7.33 (-6.39%)
PYPL   93.83 (+1.12%)
PFE   44.12 (-0.76%)
NFLX   236.73 (-1.67%)
S&P 500   3,783.28 (-0.20%)
DOW   30,273.87 (-0.14%)
QQQ   281.98 (-0.05%)
AAPL   146.40 (+0.21%)
MSFT   249.20 (+0.13%)
META   138.98 (-0.93%)
GOOGL   101.43 (-0.21%)
AMZN   120.95 (-0.12%)
TSLA   240.81 (-3.46%)
NVDA   132.09 (+0.32%)
NIO   16.04 (-4.12%)
BABA   84.39 (+0.33%)
AMD   67.94 (+0.06%)
T   15.93 (-0.99%)
MU   54.73 (+1.43%)
CGC   3.07 (-2.23%)
F   12.51 (+1.21%)
GE   67.44 (-0.15%)
DIS   100.80 (-0.63%)
AMC   7.33 (-6.39%)
PYPL   93.83 (+1.12%)
PFE   44.12 (-0.76%)
NFLX   236.73 (-1.67%)
S&P 500   3,783.28 (-0.20%)
DOW   30,273.87 (-0.14%)
QQQ   281.98 (-0.05%)
AAPL   146.40 (+0.21%)
MSFT   249.20 (+0.13%)
META   138.98 (-0.93%)
GOOGL   101.43 (-0.21%)
AMZN   120.95 (-0.12%)
TSLA   240.81 (-3.46%)
NVDA   132.09 (+0.32%)
NIO   16.04 (-4.12%)
BABA   84.39 (+0.33%)
AMD   67.94 (+0.06%)
T   15.93 (-0.99%)
MU   54.73 (+1.43%)
CGC   3.07 (-2.23%)
F   12.51 (+1.21%)
GE   67.44 (-0.15%)
DIS   100.80 (-0.63%)
AMC   7.33 (-6.39%)
PYPL   93.83 (+1.12%)
PFE   44.12 (-0.76%)
NFLX   236.73 (-1.67%)
S&P 500   3,783.28 (-0.20%)
DOW   30,273.87 (-0.14%)
QQQ   281.98 (-0.05%)
AAPL   146.40 (+0.21%)
MSFT   249.20 (+0.13%)
META   138.98 (-0.93%)
GOOGL   101.43 (-0.21%)
AMZN   120.95 (-0.12%)
TSLA   240.81 (-3.46%)
NVDA   132.09 (+0.32%)
NIO   16.04 (-4.12%)
BABA   84.39 (+0.33%)
AMD   67.94 (+0.06%)
T   15.93 (-0.99%)
MU   54.73 (+1.43%)
CGC   3.07 (-2.23%)
F   12.51 (+1.21%)
GE   67.44 (-0.15%)
DIS   100.80 (-0.63%)
AMC   7.33 (-6.39%)
PYPL   93.83 (+1.12%)
PFE   44.12 (-0.76%)
NFLX   236.73 (-1.67%)
NASDAQ:NEXI

NexImmune - NEXI News Today

$0.65
+0.02 (+2.36%)
(As of 10/5/2022 04:31 PM ET)
Add
Compare
Today's Range
$0.61
$0.66
50-Day Range
$0.55
$1.31
52-Week Range
$0.51
$15.34
Volume
99,893 shs
Average Volume
699,456 shs
Market Capitalization
$15.70 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.33
Get NexImmune News Delivered to You Automatically

Sign up to receive the latest news and ratings for NEXI and its competitors with MarketBeat's FREE daily newsletter.



NEXI Media Mentions By Week

NEXI Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

NEXI
News Sentiment

0.92

0.80

Average
Medical
News Sentiment

NEXI News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

NEXI Articles
This Week

0

1

NEXI Articles
Average Week

SourceHeadline
finance.yahoo.com logoNexImmune to Present at the H.C. Wainwright 24th Annual Global Investment Conference
finance.yahoo.com - September 9 at 4:27 PM
marketwatch.com logoNexImmune Shares Rise 17% After Service Agreement With Selexis
marketwatch.com - September 8 at 3:16 PM
msn.com logoPeering Into NexImmune's Recent Short Interest
msn.com - September 8 at 3:16 PM
finance.yahoo.com logoNexImmune Shares Jump On Immunotherapy Pact For Rare Cancers, Autoimmune Disorders
finance.yahoo.com - September 8 at 3:16 PM
finance.yahoo.com logoSelexis and NexImmune Sign Service Agreement to Advance Multiple Immunotherapies Targeting Rare Cancers and Autoimmune Disorders
finance.yahoo.com - September 8 at 10:16 AM
nasdaq.com logoHere's Why We're A Bit Worried About NexImmune's (NASDAQ:NEXI) Cash Burn Situation
nasdaq.com - September 4 at 6:08 PM
finance.yahoo.com logoBullish insiders bet US$1.7m on NexImmune, Inc. (NASDAQ:NEXI)
finance.yahoo.com - September 3 at 9:51 AM
reuters.com logoNEXI.O - Neximmune Inc | Stock Price & Latest News | Reuters
reuters.com - September 1 at 6:10 PM
markets.businessinsider.com logoNexImmune Price Target Cut By 75%, Plus Wells Fargo Lowers PT Price Target On These Stocks
markets.businessinsider.com - August 18 at 7:34 PM
finance.yahoo.com logoCan NexImmune (NASDAQ:NEXI) Afford To Invest In Growth?
finance.yahoo.com - July 18 at 9:48 AM
markets.businessinsider.com logoDow Jumps More Than 600 Points; Citigroup Tops Q2 Expectations
markets.businessinsider.com - July 15 at 2:01 PM
finance.yahoo.com logoNexImmune (NEXI) IND Gets Clearance for HPV-Related Cancer Drug
finance.yahoo.com - July 15 at 2:01 PM
nasdaq.com logoNexImmune's NEXI-003 Gets IND Clearance From FDA; Stock Jumps 25%
nasdaq.com - July 14 at 8:50 PM
finance.yahoo.com logoNexImmune Announces IND Clearance by the US FDA for NEXI-003 for the Treatment of HPV-Related Cancers
finance.yahoo.com - July 14 at 8:50 PM
benzinga.com logoNexImmune Shares Soar Following FDA's Clearance To Initial-Stage HPV Cancer Study
benzinga.com - July 14 at 6:42 PM
finance.yahoo.com logoWhat Makes NexImmune, Inc. (NEXI) a New Buy Stock
finance.yahoo.com - June 10 at 5:33 PM
seekingalpha.com logoNexImmune: Selling For Under Cash Value
seekingalpha.com - May 31 at 8:12 PM
finance.yahoo.com logoNexImmune Reports First Quarter 2022 Financial Results and Provides Business Updates
finance.yahoo.com - May 12 at 8:55 PM
finance.yahoo.com logoNexImmune Announces Appointment of Dr. Leena Gandhi to its Board of Directors
finance.yahoo.com - May 10 at 8:57 AM
finance.yahoo.com logoNexImmune Announces Preclinical Research Collaboration with Columbia University Irving Medical Center’s Herbert Irving Comprehensive Cancer Center
finance.yahoo.com - April 26 at 7:37 AM
seekingalpha.com logoNexImmune promotes insider Mathias Oelke to chief scientific officer
seekingalpha.com - April 14 at 4:55 PM
finance.yahoo.com logoNexImmune Promotes Mathias Oelke, Ph.D., To Chief Scientific Officer
finance.yahoo.com - April 14 at 4:55 PM
finance.yahoo.com logoSol Barer Is The Independent Chairman of the Board of NexImmune, Inc. (NASDAQ:NEXI) And Just Spent US$72k On Shares
finance.yahoo.com - March 27 at 4:42 PM
finance.yahoo.com logoNexImmune and Zephyr AI Announce a Strategic Partnership in Oncology for Target Discovery and Validation
finance.yahoo.com - March 17 at 5:22 PM
finance.yahoo.com logoNexImmune, Zephyr Join Forces For Oncology Target Discovery, Validation
finance.yahoo.com - March 17 at 5:22 PM
finance.yahoo.com logoNexImmune Announces Melanoma Research Collaboration with NYU Langone’s Perlmutter Cancer Center
finance.yahoo.com - March 14 at 12:04 PM
finance.yahoo.com logoNexImmune to Present at the Barclays 2022 Global Healthcare Conference
finance.yahoo.com - March 10 at 7:33 PM
seekingalpha.com logoNeximmune GAAP EPS of -$0.68
seekingalpha.com - March 10 at 4:32 AM
finance.yahoo.com logoNexImmune Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates
finance.yahoo.com - March 9 at 6:31 PM
benzinga.com logoRaymond James Maintains Outperform on NexImmune, Lowers Price Target to $13
benzinga.com - February 22 at 4:36 PM
seekingalpha.com logoNexImmune promotes chief operating officer to lead the company as CEO departs
seekingalpha.com - February 17 at 6:00 PM
finance.yahoo.com logoNexImmune Appoints Kristi Jones as Chief Executive Officer and Member of the Board of Directors
finance.yahoo.com - February 17 at 6:00 PM
finance.yahoo.com logoHere's Why We're Watching NexImmune's (NASDAQ:NEXI) Cash Burn Situation
finance.yahoo.com - February 7 at 12:44 PM
finance.yahoo.com logoNexImmune Announces Research Collaboration with Rutgers, The State University of New Jersey, Related to Neuroendocrine Tumor Targets
finance.yahoo.com - February 1 at 9:17 AM
finance.yahoo.com logoNexImmune to Participate in The Leukemia & Lymphoma Society Therapy Acceleration Program® (LLS TAP) Panel on “Expanding the Possible with Next-Generation Cell Therapies”
finance.yahoo.com - January 18 at 6:37 PM
finance.yahoo.com logoNexImmune Announces Formation of Autoimmune and Infectious Diseases Scientific Advisory Board
finance.yahoo.com - January 5 at 7:47 PM
finance.yahoo.com logoNexImmune Announces Preliminary Phase 1/2 NEXI-002 Results in Patients with Multiple Myeloma
finance.yahoo.com - December 12 at 7:51 PM
finance.yahoo.com logoNexImmune Reports Third Quarter 2021 Financial Results and Provides Business Updates
finance.yahoo.com - November 12 at 11:08 AM
finance.yahoo.com logoNexImmune to Announce Third Quarter 2021 Financial Results and Provide Corporate Update on November 12, 2021
finance.yahoo.com - November 8 at 6:40 PM
finance.yahoo.com logoWhat Percentage Of NexImmune, Inc. (NASDAQ:NEXI) Shares Do Insiders Own?
finance.yahoo.com - November 8 at 1:39 PM
finance.yahoo.com logoNexImmune to Present at The Society for Immunotherapy of Cancer 36th Anniversary Annual Meeting
finance.yahoo.com - November 3 at 9:02 AM
bizjournals.com logoMedStar Georgetown University Hospital lands $50M donation
bizjournals.com - November 2 at 8:22 PM
finance.yahoo.com logoNexImmune to Present at the 2021 Cantor Virtual Global Healthcare Conference
finance.yahoo.com - September 27 at 7:54 PM
finance.yahoo.com logoNexImmune to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
finance.yahoo.com - September 10 at 10:41 AM
finance.yahoo.com logoBullish insiders bet US$4.1m on NexImmune, Inc. (NASDAQ:NEXI)
finance.yahoo.com - August 10 at 12:00 PM
finance.yahoo.com logoNexImmune Reports Second Quarter 2021 Financial Results and Provides Business Updates
finance.yahoo.com - August 9 at 8:53 PM
finance.yahoo.com logoNexImmune to Announce Second Quarter 2021 Financial Results and Provide Corporate Update on August 9, 2021
finance.yahoo.com - July 27 at 6:36 PM
finance.yahoo.com logoNexImmune Strengthens Management Team with Key Appointments
finance.yahoo.com - July 14 at 6:19 PM
bloomberg.com logoBellicum Pharmaceuticals Inc
bloomberg.com - July 2 at 2:33 PM
barrons.com logoNexImmune Inc.
barrons.com - June 13 at 3:42 PM
Get NexImmune News Delivered to You Automatically

Sign up to receive the latest news and ratings for NEXI and its competitors with MarketBeat's FREE daily newsletter.

This page (NASDAQ:NEXI) was last updated on 10/5/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.